852947-85-4

Basic information

• Product Name: 3,5-dichloro-4-(4-methoxy-phenoxy)-benzoic acid methyl ester
• Synonyms: 3,5-dichloro-4-(4-methoxy-phenoxy)-benzoic acid methyl ester
• CAS NO: 852947-85-4
• Molecular Weight: 327.164
• Mol File: 852947-85-4.mol

Chemical Properties

• CAS DataBase Reference: 3,5-dichloro-4-(4-methoxy-phenoxy)-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-dichloro-4-(4-methoxy-phenoxy)-benzoic acid methyl ester(852947-85-4)
• EPA Substance Registry System: 3,5-dichloro-4-(4-methoxy-phenoxy)-benzoic acid methyl ester(852947-85-4)

Safety Data

• Hazardous Substances Data: 852947-85-4(Hazardous Substances Data)

Upstream product

• 3337-59-5 methyl 3,5-dichloro-4-hydroxybenzoate 

Downstream Products

• 1094307-50-2 3,5-dichloro-4-(3-formyl-4-methoxy-phenoxy)-benzoic acid methyl ester 
• 1094307-06-8 C₁₅H₁₁Cl₃O₆S 
• 852947-97-8 methyl 3,5-dichloro-4-[3'-(4-fluorobenzoyl)-4'-methoxyphenoxy]benzoate 
• 35458-42-5 3,5-dichloro-4-(4-hydroxy-phenoxy)-benzoic acid 

Relevant articles and documents

Novel Phosphinic Acid-Containing Thyromimetics

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

Efficient synthesis of structurally novel diaryl ethers by regioselective functionalization

Synthesis of structurally novel and biologically useful 3'-substituted diaryl ethers employing Cu(0) as a catalyst, followed by regioselective either sulfonylation or carbonylation, is described. Copyright Taylor & Francis Group, LLC.

NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS

The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.